Retinoic acid precursor and anticancer drug composition comprising same
A retinoic acid prodrug to which a boron functional group having a structure represented by chemical formula 1 is bound is described. The retinoic acid prodrug self-assembles to form nanoparticles. Therefore, an anticancer drug composition comprises the same as an active ingredient. According to the retinoic acid prodrug, targeted therapy of tumor cells is possible through the synergistic anticancer effect of retinoic acid and the boron functional group and the surface modification of particles. In particular, the retinoic acid prodrug enables a drug loading of 100 wt %, and thus can provide an effective anticancer drug.
1 . A retinoic acid prodrug (RABA) comprising:
a boron functional group, wherein the RABA has a structure represented by Formula 1:
2 . The RABA according to claim 1 , wherein the RABA forms nanoparticles through self-assembly.
3 . The RABA according to claim 2 , wherein the nanoparticles are formed by nano-precipitating the RABA in a solvent.
4 . The RABA according to claim 2 , wherein the nanoparticles are composed of 100% by weight of the RABA.
5 . The RABA according to claim 2 , wherein surfaces of the nanoparticles are coated with γ-polyglutamic acid (γPGA).
6 . The RABA according to claim 5 , wherein the nanoparticles target cancer cells in which gamma glutamyl transferase (GGT) is overexpressed.
7 . The RABA according to claim 1 , wherein the RABA produces quinone methide (QM) in the presence of H2O2.
8 . The RABA according to claim 1 , wherein the RABA produces hydroxybenzyl alcohol (HBA) in presence of H2O2.
9 . The RABA according to claim 1 , wherein the RABA depletes H2O2 and glutathione (GSH).
10 . The RABA according to claim 1 , wherein the RABA inhibits tumor growth.
11 . An anticancer composition comprising the RABA according to claim 1 as an active ingredient.